Study wrapper · #876
Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes: A Target Trial Emulation.
Lipska KJ, Zawack K, Yan L, et al. Annals of internal medicine. 2026.
DOI: 10.7326/annals-25-05216PubMed: 42441965
Editor's note
A well-designed target-trial emulation finding no advantage for GLP-1RAs over SGLT-2i or DPP-4i for insulin discontinuation in type 2 diabetes. Semaglutide made up most of the GLP-1RA arm but was not analyzed separately, and the cohort was overwhelmingly older male veterans, limiting generalizability. This tempers expectations that GLP-1RAs help patients come off insulin, a useful counterweight to the enthusiasm around this class.
Plain-language abstract
In a large study emulating a trial using Veterans Health records, adding a GLP-1 receptor agonist (mostly semaglutide) to basal insulin did not make patients more likely to stop insulin than two other add-on drug classes. The finding held across subgroups.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026